ITD

NUTS' Insider Threat Defense Assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace.

Retrieved on: 
Monday, January 22, 2024
NTK, Artificial intelligence, Tech, SBIR, Digital, ITD, NUTS, Department of Defence, Cryptocurrency

GLENCOE, Ill., Jan. 22, 2024 /PRNewswire-PRWeb/ -- NUTS Technologies, a leader in data-centric security solutions today announced that it has achieved "Awardable" status through the Chief Digital and Artificial Intelligence Office's (CDAO) Tradewinds Solutions Marketplace.

Key Points: 
  • Innovative Zero Trust Data solution for Insider Threat Defense will revolutionize Department of Defense (DoD) data security capabilities.
  • Recently, the company won an Air Force AFWERX SBIR Phase I grant for Insider Threat Defense using NUTS.
  • NUTS Tech's video, Insider Threat Defense (ITD), accessible only by government customers on the Tradewinds Solutions Marketplace, presents a new technical control to help mitigate Insider Threats even from privileged IT administrators with no NTK.
  • Government customers interested in viewing the video solution can create a Tradewinds Solutions Marketplace account at TradewindAI.com.

NUTS Technologies selected by AFWERX for Insider Threat Defense

Retrieved on: 
Thursday, December 21, 2023
Transfer, STTR, Policy, Federal, Small business, Small Business Innovation Research, Government, SBIR, Air force, Air Force Research Laboratory, NUTS, AFWERX, ITD, Privacy, DAF, Department of Defence, Design

GLENCOE. Ill., Dec. 21, 2023 /PRNewswire-PRWeb/ -- NUTS Technologies announces it has been selected by AFWERX for a Small Business Innovation Research (SBIR) Award for phase I in the amount of $74,277 focused on Insider Threat Defense (ITD) to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and now on December 11th, 2023, NUTS Tech will start its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.

Key Points: 
  • NUTS Technologies innovative Zero Trust Data solution for Insider Threat Defense will revolutionize Department of Defense (DoD) data security capabilities.
  • Ill., Dec. 21, 2023 /PRNewswire-PRWeb/ -- NUTS Technologies announces it has been selected by AFWERX for a Small Business Innovation Research (SBIR) Award for phase I in the amount of $74,277 focused on Insider Threat Defense (ITD) to address the most pressing challenges in the Department of the Air Force (DAF).
  • "We are honored and humbled the selection by AFWERX recognizing our innovative technical controls to combat insider threats.
  • DoD priorities such as Insider Threat Defense, JADC2, and data meshes that require accessible, resilient data across domains can benefit from the capabilities provided by NUTS."

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Trae tha Truth, ECOG, Vomiting, CYP3A4, WT, Abstract, NPM1, KMT2A, OBD, PK, DLT, TKD, Cancer, Diabetes, ORR, Clinical study design, Safety, Patient, Cohort, HSCT, SETBP1, CR, DSM-IV codes, NUP214, DOR, Dicarboxylic acid, CRi, ASH, CD135, QT interval, RFS, FLT3, Arm, Cellular, FMS, Transplant, ALL, Toxic leukoencephalopathy, Gene family, Survival, Postcholecystectomy syndrome, DS, Trial of the century, Incidence, CRC, Infrared spectroscopy correlation table, AL, Osteopathic medicine in Canada, MN1, BID, CNS, KRAS, ATD, NUP98, Society, WBC, Pharmacokinetics, CLL, Acute leukemia, Common, ITD, Toxicity, AML, Cardiovascular disease, Pharmaceutical industry, Dentistry, Vaccine, Decitabine, DLBCL

Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.

Key Points: 
  • Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.
  • Methods: Doses of BMF-219 are escalated independently for each indication, initially in single-subject cohorts followed by a “3 + 3” design.
  • A subsequent amendment introduced quotas for KMT2Ar (MLL1r), NPM1 and other known menin-dependent mutations: CEBP/A, MLL1-PTD, MN1, NUP98, NUP214, PICALM-AF10, SETBP1.
  • The study was initiated in July 2023 and will enroll ~110 participants at approximately 30 sites.

NIKOLA ANNOUNCES EXPANSION OF DEALER SALES AND SERVICE NETWORK INTO CANADA IN PARTNERSHIP WITH ITD INDUSTRIES

Retrieved on: 
Friday, September 15, 2023
Heart, Autumn, Partnership, Hydrogen, ITD, CAD, HYLA, Nikola, Carbon, Government, Climate change, Investment, Nikola Corporation, Growth, Transport, Airline, Renewable energy

"Bringing ITD on board as our first Canadian dealer is an exciting move for Nikola.

Key Points: 
  • "Bringing ITD on board as our first Canadian dealer is an exciting move for Nikola.
  • We are extremely excited to be leveraging our brand, reputation and new partnership with Nikola to be that accelerant here in Canada."
  • ITD will be promoting Nikola's zero-emission trucks across its national sales channels and is a qualified dealer under the Federal government's iMHZEV program.
  • ITD will be holding a launch event for industry and other interested stakeholders in the Fall of 2023 to share more about its partnership with Nikola.

VANFLYTA® (quizartinib) Now Available from Onco360

Retrieved on: 
Wednesday, August 9, 2023
FDA, Pharmaceutical, Health, Oncology, Maintenance, ITD, Pharmacy, HSCT, Acute myeloid leukemia, AML, Specialty pharmacy, Patient, Risk, Daiichi Sankyo, HR, FLT3, American Cancer Society, United, Leukemia, Death, Caregiver, Pharmaceutical industry, Nursing

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Daiichi Sankyo to be a specialty pharmacy partner for VANFLYTA® (quizartinib).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Daiichi Sankyo to be a specialty pharmacy partner for VANFLYTA® (quizartinib).
  • VANFLYTA is not indicated as a maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.
  • “Onco360 is grateful for the opportunity to partner with the team at Daiichi Sankyo and become a specialty pharmacy provider for VANFLYTA patients,” said Benito Fernandez, Chief Commercial Officer.
  • It is the first and only FLT3 inhibitor to be approved by the FDA specifically for FLT3-ITD positive AML across the three phases of treatment – induction, consolidation, and maintenance in patients without transplant.

Seed Group onboards Los Angeles-based Resecurity to protect the digital ecosystem in MENA

Retrieved on: 
Wednesday, July 19, 2023
Platform as a service, Partnership, Sheikh Said, Private, Health, IDP, GCC, Cyber threat intelligence, Telecommunications, FRM, EPP, ITD, Vulnerability assessment, Risk assessment, Intelligence, Intelligence Identities Protection Act, Private officer of arms, Government, Endpoint security, Platform, Machine learning, Risk management, CTI, Artificial intelligence, LOS, Gulf Cooperation Council, DRM, Airline, Retail, Medical device, Fraud

With this strategic partnership, Seed Group and Resecurity are set to reshape the cybersecurity landscape in the Middle East, empowering organisations with advanced tools and techniques to proactively combat emerging threats in an increasingly digital world.

Key Points: 
  • With this strategic partnership, Seed Group and Resecurity are set to reshape the cybersecurity landscape in the Middle East, empowering organisations with advanced tools and techniques to proactively combat emerging threats in an increasingly digital world.
  • The collaboration between Seed Group and Resecurity aims to equip regional businesses with the latest cybersecurity solutions, ensuring their readiness to navigate through the rapidly changing technology landscapes that govern the corporate world globally.
  • Through this partnership, Seed Group will guide Resecurity in expanding its presence in the UAE and the region.
  • Seed Group has established itself as a notable force in the technology, healthcare, hospitality, and telecommunications landscape in the Middle East.

Efficient and Eco-Friendly: NEXT-ChemX Unlocking Lithium Extraction Potential

Retrieved on: 
Monday, July 10, 2023
Lithium, DLE, ITD, Magnesium, Noetics, Government, Calcium, Corporation, Fresh water, Potassium

We are on the verge of a new wave of lithium availability due to breakthroughs in efficient, environmentally friendly extraction methods.

Key Points: 
  • We are on the verge of a new wave of lithium availability due to breakthroughs in efficient, environmentally friendly extraction methods.
  • NEXT-ChemX (CHMX) says lithium availability on the verge of new wave with efficient, eco-friendly extraction methods.
  • Recognizing DLE's massive potential and effectiveness, Chile, a global leader in lithium deposits, has made DLE mandatory for all new extraction operations.
  • NEXT-ChemX Corporation (CHMX), a Nevada-based company, is field-testing a groundbreaking membrane-based ion extraction process called ion-Targeting Direct Extraction (iTDE).

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Retrieved on: 
Thursday, April 13, 2023
CLL, NRAS, KRAS, MYC, AACR, Molecule, TP53, Chronic lymphocytic leukemia, Menin, ITD, Acute leukemia, American Association for Cancer Research, MEK, Doctor of Philosophy, BTK, Gene expression profiling, MEN1, NOTCH1, AML, BCL2, Patient, DSM-IV codes, Proteasome inhibitor, Cancer, Acute myeloid leukemia, Growth, Leukemia, Therapy, Gene, Disease, Pharmaceutical industry, Vaccine, Biology, FLT3

Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.

Key Points: 
  • Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.
  • Menin is an epigenetic protein that drives oncogenic function through transcriptional regulation directed by its interactions with various protein partners.
  • Additionally, we show benefit of combinatorial approaches of menin and FLT3 covalent inhibitors with MEK and BCL2 blockade.
  • These data provide initial pre-clinical evidence for combining pathway specific inhibitors as a promising therapeutic strategy for further investigation in acute leukemia.

Contractual Partnership JV Signed for Lithium Extraction in Bolivia

Retrieved on: 
Tuesday, March 28, 2023
Lithium, ITD, Altitude, Partnership, Partner, Noetics, Water, OTC, Kinetics, Environment, YLB

Under this agreement NEXT-ChemX and Clontarf (together the “Partners”) will establish a contractual Partnership domiciled in Texas and known as ‘Clontarf NEXT-ChemX JV’.

Key Points: 
  • Under this agreement NEXT-ChemX and Clontarf (together the “Partners”) will establish a contractual Partnership domiciled in Texas and known as ‘Clontarf NEXT-ChemX JV’.
  • The Partnership will provide the Partners with a vehicle to enable them to demonstrate the technical, commercial and environmental feasibility of NEXT-ChemX’s ion-Targeting Direct Extraction technology (“iTDE Technology”) in Bolivia.
  • To obtain this exclusive right for the Partnership, Clontarf will pay $500,000 to NEXT-ChemX.
  • Benton Wilcoxon, CEO of Next-ChemX commented: “We are confident that our iTDE technology will be effective with lithium extraction.

French Blood Establishment (EFS) & Brenus Pharma Partner for the GMP Production of STC-1010, an Innovative Therapy Against Colorectal Cancer

Retrieved on: 
Monday, March 27, 2023
Medical Devices, Infectious Diseases, Hospitals, Clinical Trials, Biometrics, Other Health, Biotechnology, Pharmaceutical, Health, Oncology, Partnership, Education, CSO, ITD, Cancer, STC, Synthase, EMA, Pharmacist, Patient, European, Nursing, Colorectal cancer, Immune system, ANSM, Certification, EFS, MTI, FDA, Pharmaceutical industry, Vaccine

The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise.

Key Points: 
  • The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise.
  • This collaboration is part of a shared vision: developing the French bioproduction sector nationally and internationally.
  • This public-private partnership aims for a long-term perspective and will lead in 2023 to the production of clinical batches for the Fist-In-Human study of STC-1010, Brenus Pharma's lead candidate, targeting colorectal cancer.
  • We are 10,000 professionals, including doctors, nurses, biologists, technicians, pharmacists, collection teams, researchers, administrative staff… driven by the same vital mission.